Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now owns 2,926 shares in the company, valued at $125,291.32. This represents a 20.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $41.32 on Friday. The firm has a 50 day moving average of $42.95 and a two-hundred day moving average of $40.66. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $48.89. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -20.46 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same period in the prior year, the company posted ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Ratings Changes

MIRM has been the subject of several recent analyst reports. Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, Citigroup increased their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $57.10.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MIRM. Lord Abbett & CO. LLC bought a new stake in Mirum Pharmaceuticals during the third quarter worth approximately $28,913,000. Geode Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after buying an additional 29,017 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after buying an additional 75,000 shares during the period. Barclays PLC boosted its holdings in shares of Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company’s stock worth $9,592,000 after buying an additional 10,824 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $215,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.